The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Somatostatin Analogs-Global Market Insights and Sales Trends 2024
Synopsis
Somatostatin analogues stop your body from making too many hormones. They can reduce the symptoms of carcinoid syndrome and may slow down tumour growth.
The global Somatostatin Analogs market size is expected to reach US$ 6543.2 million by 2029, growing at a CAGR of 5.0% from 2023 to 2029. The market is mainly driven by the significant applications of Somatostatin Analogs in various end use industries. The expanding demands from the Acromegaly, Carcinoid Syndrome, Neuroendocrine Tumor and Cushing Syndrome, are propelling Somatostatin Analogs market. Octreotide, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Lanreotide segment is estimated at % CAGR for the next seven-year period.
Somatostatin is a protein made naturally in the body. It is made by: a gland in the brain (hypothalamus), the stomach, the pancreas and the bowel. Somatostatin can slow down hormone production, including many of the gut hormones, slows down the emptying of the stomach and bowel, controls the release of hormones made by the pancreas, including insulin and, slows down or stops the release of growth hormones. Rise in the research and development and launch of novel drug therapies are the factors driving the growth of somatostatin analogs over the forecast period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Somatostatin Analogs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Somatostatin Analogs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Somatostatin Analogs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Somatostatin Analogs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Somatostatin Analogs covered in this report include Novartis, Peptron, Chiasma and Ipsen Biopharmaceutical, etc.
The global Somatostatin Analogs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Peptron
Chiasma
Ipsen Biopharmaceutical
Global Somatostatin Analogs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Somatostatin Analogs market, Segment by Type:
Octreotide
Lanreotide
Pasireotide
Global Somatostatin Analogs market, by Application
Acromegaly
Carcinoid Syndrome
Neuroendocrine Tumor
Cushing Syndrome
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Somatostatin Analogs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Somatostatin Analogs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Somatostatin analogues stop your body from making too many hormones. They can reduce the symptoms of carcinoid syndrome and may slow down tumour growth.
The global Somatostatin Analogs market size is expected to reach US$ 6543.2 million by 2029, growing at a CAGR of 5.0% from 2023 to 2029. The market is mainly driven by the significant applications of Somatostatin Analogs in various end use industries. The expanding demands from the Acromegaly, Carcinoid Syndrome, Neuroendocrine Tumor and Cushing Syndrome, are propelling Somatostatin Analogs market. Octreotide, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Lanreotide segment is estimated at % CAGR for the next seven-year period.
Somatostatin is a protein made naturally in the body. It is made by: a gland in the brain (hypothalamus), the stomach, the pancreas and the bowel. Somatostatin can slow down hormone production, including many of the gut hormones, slows down the emptying of the stomach and bowel, controls the release of hormones made by the pancreas, including insulin and, slows down or stops the release of growth hormones. Rise in the research and development and launch of novel drug therapies are the factors driving the growth of somatostatin analogs over the forecast period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Somatostatin Analogs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Somatostatin Analogs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Somatostatin Analogs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Somatostatin Analogs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Somatostatin Analogs covered in this report include Novartis, Peptron, Chiasma and Ipsen Biopharmaceutical, etc.
The global Somatostatin Analogs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Peptron
Chiasma
Ipsen Biopharmaceutical
Global Somatostatin Analogs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Somatostatin Analogs market, Segment by Type:
Octreotide
Lanreotide
Pasireotide
Global Somatostatin Analogs market, by Application
Acromegaly
Carcinoid Syndrome
Neuroendocrine Tumor
Cushing Syndrome
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Somatostatin Analogs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Somatostatin Analogs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Somatostatin Analogs Market Overview
1.1 Somatostatin Analogs Product Overview
1.2 Somatostatin Analogs Market Segment by Type
1.2.1 Octreotide
1.2.2 Lanreotide
1.2.3 Pasireotide
1.3 Global Somatostatin Analogs Market Size by Type
1.3.1 Global Somatostatin Analogs Market Size Overview by Type (2018-2029)
1.3.2 Global Somatostatin Analogs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Somatostatin Analogs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Somatostatin Analogs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Somatostatin Analogs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Somatostatin Analogs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Somatostatin Analogs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Somatostatin Analogs Sales Breakdown by Type (2018-2023)
2 Global Somatostatin Analogs Market Competition by Company
2.1 Global Top Players by Somatostatin Analogs Sales (2018-2023)
2.2 Global Top Players by Somatostatin Analogs Revenue (2018-2023)
2.3 Global Top Players by Somatostatin Analogs Price (2018-2023)
2.4 Global Top Manufacturers Somatostatin Analogs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Somatostatin Analogs Market Competitive Situation and Trends
2.5.1 Somatostatin Analogs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Somatostatin Analogs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Somatostatin Analogs as of 2022)
2.7 Date of Key Manufacturers Enter into Somatostatin Analogs Market
2.8 Key Manufacturers Somatostatin Analogs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Somatostatin Analogs Status and Outlook by Region
3.1 Global Somatostatin Analogs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Somatostatin Analogs Historic Market Size by Region
3.2.1 Global Somatostatin Analogs Sales in Volume by Region (2018-2023)
3.2.2 Global Somatostatin Analogs Sales in Value by Region (2018-2023)
3.2.3 Global Somatostatin Analogs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Somatostatin Analogs Forecasted Market Size by Region
3.3.1 Global Somatostatin Analogs Sales in Volume by Region (2024-2029)
3.3.2 Global Somatostatin Analogs Sales in Value by Region (2024-2029)
3.3.3 Global Somatostatin Analogs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Somatostatin Analogs by Application
4.1 Somatostatin Analogs Market Segment by Application
4.1.1 Acromegaly
4.1.2 Carcinoid Syndrome
4.1.3 Neuroendocrine Tumor
4.1.4 Cushing Syndrome
4.1.5 Others
4.2 Global Somatostatin Analogs Market Size by Application
4.2.1 Global Somatostatin Analogs Market Size Overview by Application (2018-2029)
4.2.2 Global Somatostatin Analogs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Somatostatin Analogs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Somatostatin Analogs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Somatostatin Analogs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Somatostatin Analogs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Somatostatin Analogs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Somatostatin Analogs Sales Breakdown by Application (2018-2023)
5 North America Somatostatin Analogs by Country
5.1 North America Somatostatin Analogs Historic Market Size by Country
5.1.1 North America Somatostatin Analogs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Somatostatin Analogs Sales in Volume by Country (2018-2023)
5.1.3 North America Somatostatin Analogs Sales in Value by Country (2018-2023)
5.2 North America Somatostatin Analogs Forecasted Market Size by Country
5.2.1 North America Somatostatin Analogs Sales in Volume by Country (2024-2029)
5.2.2 North America Somatostatin Analogs Sales in Value by Country (2024-2029)
6 Europe Somatostatin Analogs by Country
6.1 Europe Somatostatin Analogs Historic Market Size by Country
6.1.1 Europe Somatostatin Analogs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Somatostatin Analogs Sales in Volume by Country (2018-2023)
6.1.3 Europe Somatostatin Analogs Sales in Value by Country (2018-2023)
6.2 Europe Somatostatin Analogs Forecasted Market Size by Country
6.2.1 Europe Somatostatin Analogs Sales in Volume by Country (2024-2029)
6.2.2 Europe Somatostatin Analogs Sales in Value by Country (2024-2029)
7 Asia-Pacific Somatostatin Analogs by Region
7.1 Asia-Pacific Somatostatin Analogs Historic Market Size by Region
7.1.1 Asia-Pacific Somatostatin Analogs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Somatostatin Analogs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Somatostatin Analogs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Somatostatin Analogs Forecasted Market Size by Region
7.2.1 Asia-Pacific Somatostatin Analogs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Somatostatin Analogs Sales in Value by Region (2024-2029)
8 Latin America Somatostatin Analogs by Country
8.1 Latin America Somatostatin Analogs Historic Market Size by Country
8.1.1 Latin America Somatostatin Analogs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Somatostatin Analogs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Somatostatin Analogs Sales in Value by Country (2018-2023)
8.2 Latin America Somatostatin Analogs Forecasted Market Size by Country
8.2.1 Latin America Somatostatin Analogs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Somatostatin Analogs Sales in Value by Country (2024-2029)
9 Middle East and Africa Somatostatin Analogs by Country
9.1 Middle East and Africa Somatostatin Analogs Historic Market Size by Country
9.1.1 Middle East and Africa Somatostatin Analogs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Somatostatin Analogs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Somatostatin Analogs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Somatostatin Analogs Forecasted Market Size by Country
9.2.1 Middle East and Africa Somatostatin Analogs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Somatostatin Analogs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Novartis
10.1.1 Novartis Company Information
10.1.2 Novartis Introduction and Business Overview
10.1.3 Novartis Somatostatin Analogs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Novartis Somatostatin Analogs Products Offered
10.1.5 Novartis Recent Development
10.2 Peptron
10.2.1 Peptron Company Information
10.2.2 Peptron Introduction and Business Overview
10.2.3 Peptron Somatostatin Analogs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Peptron Somatostatin Analogs Products Offered
10.2.5 Peptron Recent Development
10.3 Chiasma
10.3.1 Chiasma Company Information
10.3.2 Chiasma Introduction and Business Overview
10.3.3 Chiasma Somatostatin Analogs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Chiasma Somatostatin Analogs Products Offered
10.3.5 Chiasma Recent Development
10.4 Ipsen Biopharmaceutical
10.4.1 Ipsen Biopharmaceutical Company Information
10.4.2 Ipsen Biopharmaceutical Introduction and Business Overview
10.4.3 Ipsen Biopharmaceutical Somatostatin Analogs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Ipsen Biopharmaceutical Somatostatin Analogs Products Offered
10.4.5 Ipsen Biopharmaceutical Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Somatostatin Analogs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Somatostatin Analogs Industrial Chain Analysis
11.4 Somatostatin Analogs Market Dynamics
11.4.1 Somatostatin Analogs Industry Trends
11.4.2 Somatostatin Analogs Market Drivers
11.4.3 Somatostatin Analogs Market Challenges
11.4.4 Somatostatin Analogs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Somatostatin Analogs Distributors
12.3 Somatostatin Analogs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
